Abstract 2089P
Background
Febrile neutropenia (FN) resulting from myelosuppressive chemotherapy drugs, have the potential to necessitate dose reduction or treatment delays, thus compromising the overall efficacy of treatment. This study aims to analyze the incidence of FN and related adverse drug reactions in cancer patients who receive prophylaxis with PEG-rhG-CSF (a long-acting granulocyte colony-stimulating factor).
Methods
This real-world study was conducted as a multicenter, retrospective, observational research involving adult cancer patients who received chemotherapy with PEG-rhG-CSF prophylactic. The study focused on several variables, including baseline characteristics and incidence of FN. Descriptive analysis was performed by using IBM SPSS Statistics 27.
Results
24,199 patients were enrolled from 575 hospitals across China between June 2022 and January 2023. The chemotherapy cycle records encompassed 1to 20 cycle. Among the enrolled patients, breast cancer was the most prevalent tumor type, accounting for 33.6% (N=8,131) of the cases. FN incidence across all cycles was 0.054% and it was 0.055% and 0.053% among patients receiving PEG-rhG-CSF as primary and secondary prophylaxis. These rates were significantly lower than the previously reported data of 13% to 21% from a retrospective cohort study involving patients with or without prophylaxis. Overall, FN occurred across the first to eighth cycles with the highest incidence observed in cycle 1 (52.50%). 1,659 records (2.25%) reported adverse events related to PEG-rhG-CSF. The most commonly observed adverse effect was musculoskeletal pain, accounting for 1.53% of the cases, followed by fatigue(0.60%) and allergic reactions(0.07%). Furthermore, 90.78% of adverse reactions were categorized as primary or secondary adverse reactions.
Conclusions
Under PEG-rhG-CSF prophylaxis, cancer patients exhibited a low incidence of FN which primarily occurred in the initial cycle of chemotherapy. Importantly, the administration of PEG-rhG-CSF was well tolerated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06